

# Toronto Global Cancer Control Conference

Creating the Future



March 1 to 3, 2018

Toronto, Canada



# PARTNERSHIP PACKAGE



# TABLE OF CONTENTS

---

1. MESSAGE FROM THE CO-CHAIRS	1
Conference Objectives	2
International Scientific Advisory Committee	3
Key Conference Topics	11
Potential Speakers	12

---

2. PROPOSED CONFERENCE PROGRAM	14
--------------------------------	----

---

3. PARTNERSHIP OPPORTUNITIES	17
Partnership Levels & Benefits	18

# 1 | MESSAGE FROM THE CO-CHAIRS

Dear Industry Partners,

On behalf of the Dalla Lana School of Public Health and the Princess Margaret Cancer Centre, we invite you to join us at the Toronto Global Cancer Control Conference (TGCCC) in Toronto, ON from March 1 to 3, 2018!

With cancer rapidly becoming one of the world's most common diseases and causes of death, especially in low and middle-income countries (LMICs), this conference will emphasize Canada's leadership role in the fight against cancer around the world. We will launch a global initiative to work with global leaders to bend down the curve of cancer rates and deaths as the global community did with both TB and AIDS 20 years ago. We will look at cancer control and technological innovations in Canada and LMICs, drug pricing in health systems and how systems should be organized, engage a new generation of health leaders and form partnerships to scale up global solutions.

As a featured industry partner, your commitments will:

- Raise Canada's global leadership in an emerging and relatively untapped area of quality cancer care
- Engage key leaders in academia, industry, and civil society to expand access to cost-effective cancer care worldwide
- Enable follow up on scientific and business opportunities (e.g. public private partnerships on mobilizing therapies)
- Create the foundation of industry partnerships who will support the launch of the Canadian Global Cancer Network

With keynote addresses by experts from Canada and abroad, Davos-style panels and rapid fire sessions, café-style discussions, poster displays and countless opportunities for networking between industry, researchers in the beginning of their careers, and those more seasoned, and policy makers from Canada and emerging markets. It promises to be a productive and game-changing conference.

We hope you will join us!

Sincerely,



A handwritten signature in black ink, appearing to read 'P. Jha'.

Dr. Prabhat Jha – Conference Co-Chair  
Chair in Disease Control, Dalla Lana School of  
Public Health  
Director, Centre for Global Health Research



A handwritten signature in black ink, appearing to read 'Mary Gospodarowicz'.

Dr. Mary Gospodarowicz – Conference Co-Chair  
Medical Director, Princess Margaret Cancer  
Centre



As a high profile conference on Canada's role in global cancer prevention and treatment, TGCCC will play host to a variety of government and policy influencers from low- and middle-income countries (LMICs), international experts in cancer research, clinical care and palliation, policy advisors, industry experts and patient advocates.

With a focus on bi-directional learning, Canadian health professionals will exchange with LMIC health leaders proven, cost-effective and innovative approaches to cancer control, community pain treatment protocols and drug policy, in order to inform best practice around the world.

Absolute cancer burdens are rising fast, specifically in LMICs. Canada has had great success reducing deaths by breast and lung cancer through a focus on prevention, treatment and tobacco control legislation. These approaches are generally low cost and can easily be implemented in LMICs. This conference will launch a coordinated effort to bend down the curve of global rates of cancer.

## CONFERENCE OBJECTIVES

- To explore next generation approaches to cancer control, disruptive innovation and foster transdisciplinary engagement.
- To build together partners, stimulate networks, foster and develop young leaders.
- To examine critical and potentially synergistic link between women's and child health initiatives and global cancer control.

## INTERNATIONAL SCIENTIFIC ADVISORY BOARD

### Mary Gospodarowicz – Co-Chair



Mary Gospodarowicz is Professor of Radiation Oncology at the University of Toronto, the Medical Director of the Princess Margaret Cancer Centre at the University Health Network, and the Regional Vice President of Cancer Care Ontario. She is past Chair of Radiation Oncology at the University of Toronto. She holds specialty certifications in internal medicine, radiation oncology, and medical oncology and her clinical practice involves lymphomas and genitourinary cancers. Her research focused on clinical trials evaluating radiation therapy, image-guided precision radiotherapy, and cancer survivorship. Her current interests include global cancer control, global access to radiotherapy, and quality cancer care.

Professor Gospodarowicz is Past-President of the Union for International Cancer Control (UICC). She proudly participates in the work of the Global Task Force on Cancer Care and Control of Harvard Global Equity Initiative and the HGEI-Lancet Commission on Global Access to Pain Control & Palliative Care. Under the auspices of UICC and Lancet Oncology, the Global Task Force on Radiotherapy produced a seminal report on ‘Expanding the global access to radiotherapy’ that provided evidence for the demand, efficacy, and cost effectiveness of radiotherapy.

She is the Associate Editor of Cancer Biology and Medicine and the Journal of Global Oncology and a longstanding member of ASCO, a Fellow of the American Society in Radiation Oncology (ASTRO), Honorary Fellow of the Royal College of Radiologists in the United Kingdom, and Honorary Fellow of the Faculty of Radiologists in the Royal College of Surgeons of Ireland. She is an honorary member of the European Society of Therapeutic Radiology and Oncology (ESTRO), the Scientific Association of Swiss Radiation Oncology (SASRO), and the German Society for Radio-oncology (DEGRO).

She is a recipient of numerous awards including the Gordon Richards Lectureship from the Canadian Association of Radiation Oncologists, the May Cohen Award for Women Mentors from the Canadian Medical Association, the Janeway Medal from the American Radium Society, the ESTRO Lifetime Achievement Award, the ASTRO Gold Medal, and the Harold O. Warwick Prize for outstanding achievements in cancer control research from the Canadian Cancer Society. In 2015, she was appointed Officer of the Order of Canada.

### Prabhat Jha – Co-Chair



Prabhat Jha is an Endowed Professor in Global Health and Epidemiology at the University of Toronto and Canada Research Chair at the Dalla Lana School of Public Health, and the founding Director of the Centre for Global Health Research.

Professor Jha is a lead investigator of the Million Death Study in India, which quantifies the causes of premature mortality in over 2 million homes. His publications on tobacco control have enabled a global treaty now signed by over 180 countries. He founded the Statistical Alliance for Vital Events, which focuses on reliable measurement of premature mortality worldwide. Earlier, Professor Jha served in senior roles at the World Health Organization and the World Bank. He was made an Officer of the Order of Canada in 2012. Professor Jha holds an M.D. from the University of Manitoba and a D.Phil. from Oxford University, where he studied as a Rhodes Scholar.

## Sir George Alleyne



Sir George Alleyne, a native of Barbados, became Director of the Pan American Health Organization (PAHO), Regional Office of the World Health Organization (WHO) on 1 February 1995 and completed a second four-year term on 31 January 2003. In 2003 he was elected Director Emeritus of the PASB. From February 2003 until December 2010 he was the UN Secretary General's Special Envoy for HIV/AIDS in the Caribbean. In October 2003 he was appointed Chancellor of the University of the West Indies. He currently holds an Adjunct professorship on the Bloomberg School of Public Health, Johns Hopkins University.

Dr. Alleyne has received numerous awards in recognition of his work, including prestigious decorations and national honours from many countries of the Americas. In 1990, he was made Knight Bachelor by Her Majesty Queen Elizabeth II for his services to Medicine. In 2001, he was awarded the Order of the Caribbean Community, the highest honour that can be conferred on a Caribbean national.

## Sanchia Aranda



Professor Sanchia Aranda was appointed as CEO of Cancer Council Australia in August 2015. In this role Sanchia leads cancer policy and advocacy development, ensuring a strong evidence base is used to inform cancer control in Australia. She also holds academic appointments with the School of Health Sciences, University of Melbourne and the Faculty of Nursing, University of Sydney and is a research fellow at the Peter MacCallum Cancer Centre. She has 38 years' experience in cancer control and has held roles in healthcare, research, tertiary education and government prior to joining the not-for-profit sector. She has held significant leadership roles in Australian

Cancer Control, including 8 years on the Advisory Council for Cancer Australia (2006-2015).

Sanchia also has extensive international cancer control experience, with 16 years on the board of the International Society of Nurses in Cancer Care, including 4 as President (2006-2010). She is the President for the Union for International Cancer Control and has been on the board of UICC for 6 years. She is also a board member for the International Collaboration on Cancer Reporting. Her contributions to cancer control have been recognized nationally and internationally through awards and keynote speaker invitations. In 2013 she was named the 4th Peter MacCallum Cancer Centre Distinguished Fellow for her contributions to Cancer Nursing and in 2016 received the International Society of Nurses in Cancer Care Distinguished Merit award.

## Rifat Atun



Rifat Atun is Professor of Global Health Systems at Harvard University and Director of the Health Systems Cluster. He is the Faculty Chair for the Harvard Ministerial Leadership Initiative. In 2006-2014 he was Professor of International Health Management at Imperial College London.

In 2008-12 Professor Atun served as a member of the Executive Management Team of the Global Fund to Fight AIDS, Tuberculosis and Malaria in Switzerland as the Director of the Strategy, Performance and Evaluation.

Professor Atun's research focuses on global health systems, global health financing, and innovation in health systems. He has worked extensively with governments, the UK DFID, the World Bank, World Health Organization, and other international agencies to design, implement and evaluate health system reforms.

Dr. Atun studied medicine at University of London as a Commonwealth Scholar and undertook his postgraduate medical studies and MBA at University of London and Imperial College London. He is a Fellow of the Faculty of Public Health of the Royal College of Physicians (UK), a Fellow of the Royal College of General Practitioners (UK), and a Fellow of the Royal College of Physicians (UK).

## Otis Webb Brawley



Otis Webb Brawley is an acknowledged global leader in the field of cancer prevention and control. As the chief medical and scientific officer and executive vice president of the American Cancer Society, he is responsible for promoting the goals of cancer prevention, early detection, and quality treatment through cancer research and education. He champions efforts to decrease smoking, improve diet, and provide the critical support cancer patients need. He also guides efforts to enhance and focus the Nation's research program, upgrade the Society's advocacy capacity, and concentrate community cancer control efforts in areas where they will be most effective. Dr. Brawley currently serves as professor of hematology, oncology, medicine and epidemiology at Emory University. He is also a medical consultant to the Cable News Network (CNN). From April of 2001 to November of 2007, he was director of the Georgia Cancer Center at Grady Memorial Hospital in Atlanta, and deputy director for cancer control at the Winship Cancer Institute at Emory University. He previously served as a member of the Society's Prostate Cancer Committee, co-chaired the U.S. Surgeon General's Task Force on Cancer Health Disparities, and filled a variety of positions at the National Cancer Institute (NCI), most recently serving as Assistant Director.

Dr. Brawley has served on a number of advisory committees including: the NIH Committee on Women's Health; the Centers for Disease Control and Prevention Advisory Committee on Breast Cancer in Young Women; the Centers for Disease Control and Prevention Breast and Cervical Cancer Early Detection and Control Advisory Committee; and the Food and Drug Administration Oncologic Drug Advisory Committee. He chaired the NIH Consensus Panel on the Treatment of Sickle Cell Disease.

He has been listed by Castle Connelly as one of America's Top Doctors for Cancer. Among numerous other awards, he was a Georgia Cancer Coalition Scholar and received the Key to St. Bernard Parish for work in the U.S. Public Health Service in the aftermath of Hurricane Katrina. He is a fellow of the American Society of Clinical Oncology, a Fellow of the American College of Epidemiology and one of less than 1300 physicians to be named a Master of the American College of Physicians in its more than 100 year history. Dr. Brawley is also a member of the National Academy of Medicine.

Dr. Brawley graduated from the University of Chicago, Pritzker School of Medicine; trained in internal medicine at Case-Western Reserve University, and in medical oncology at the National Cancer Institute.

## David Collingridge



David Collingridge has been Editor-in-Chief of The Lancet Oncology since March 2002, and is also the Publishing Director for The Lancet's Specialty Journals. Prior to his appointments at The Lancet, he gained a PhD in Tumour Biology from the Gray Cancer Institute/University College London, UK, and held research posts in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, Hammersmith Hospital, London, UK. Dr Collingridge has published numerous peer-review articles, editorials, opinion pieces, and news reports, and has co-authored a text book on radiobiology. He currently also holds the position of Clinical Associate Professor of Radiation Medicine at Hofstra/Northwell Health, Lake Success, NY, USA.

## Anil D'Cruz



Anil K D'Cruz is Director at the Tata Memorial Hospital, Mumbai, India and Professor and Surgeon in the Department of Head and Neck Surgery. He graduated from St.John's Medical College, Bangalore in 1984 & went on to complete his Masters in general surgery at the Mumbai University. He is also a Diplomat of the National Board, New Delhi. In recognition of his professional standing in the field of Surgery, he was awarded the Honorary FRCS from the Royal College of Surgeons, London.

Dr. D'Cruz has over 30 years' experience in the field of Surgical Oncology focussing primarily on head and neck cancers. His major areas of interest are management of neck metastasis, conservative laryngeal surgery, cancers of the oral cavity, thyroid, quality of life issues and global health. He is actively involved in research and plays a pivotal role in a number of trials. As principal investigator, he has successfully published results of a prospective randomized controlled trial evaluating the role of elective neck dissection in the management of early oral cancers that is practice defining. In addition, he has been principal investigator of a Phase I trial evaluating the role of Interstitial Photodynamic Therapy (PDT) in advanced cancers and was the Global Principal Investigator for a trial evaluating the role of PDT in recurrent, refractory head and neck tumours. He is also the principal investigator of multicentric, multinational trials studying the role of targeted therapy in head and neck cancers in the concurrent, adjuvant and the palliative setting. He has been involved in research on the use of curcumin, proteomics, gene therapy in head and neck cancer.

Dr. D'Cruz has leadership position in a number of cancer organizations. He is on the Board of Directors on the Union International on Cancer Control, Geneva as well as Governing Council, Foundation of Head and Neck Oncology, India. He is also on the Governing Board/Scientific Advisory Board of various leading institutions such as Gulf Medical University, All India Institute of Medical Sciences, Rishikesh, National Institute of Biomedical Genomics, Kalyani amongst others. He has been past-president of the Asian Society of Head and Neck Oncology, Foundation of Head and Neck Oncology, India; Task force, Department of Biotechnology, Government of India, and Cancer guidelines, Indian Council of Medical Research.

Dr D'Cruz is a member of numerous professional bodies in the country which include, The Indian Society of Surgical Oncology, Association of Surgeons of India, Indian Society for Cancer Research, Indian Association of Surgical Oncology, Foundation of Head and Neck Oncology, Indian Society of Head and Neck Oncology and the Action council for Tobacco Control.



Dr D'Cruz has over 200 peer reviewed publications, and chapters to his name. He is an editor of a two-volume book on Head and neck surgery and also the to-be-released Manual of Clinical Oncology and Hamilton Bailey Clinical Signs. He has delivered over 300 invited lectures and orations and has been visiting professor to several institutions, both nationally and internationally. He is a member of the Editorial Board of Head Neck journals and also is a reviewer for several scientific journals both national and international.

## Hellen Gelband



Hellen Gelband is Associate Director for Policy at the Center for Disease Dynamics, Economics & Policy (CDDEP). Her work spans infectious disease, particularly malaria and antibiotic resistance, and non-communicable disease policy, mainly in low- and middle-income countries. Before joining CDDEP, she conducted policy studies at the (former) Congressional Office of Technology Assessment, the Institute of Medicine of the U.S. National Academies, and a number of international organizations. She is an editor in the Cochrane Infectious Diseases Group and an editor of Disease Control Priorities, 3rd edition. At CDDEP, she has led the Global Antibiotic Resistance Partnership (GARP) since its inception in 2008.

## Dean Jamison



Dean Jamison is Professor Emeritus of Global Health at the University of California, San Francisco. He previously served as Professor of Global Health at the University of Washington (2008 - 13) and as the T. & G. Angelopoulos Visiting Professor of Public Health and International Development in the Harvard Kennedy School and the Harvard School of Public Health (2006 - 08). Prior to that, Jamison had been at the University of California, Los Angeles (1988 - 2006) and at the World Bank (1976 - 1988). His last position at the World Bank was Director, World Development Report Office and lead author for the Bank's 1993 World Development Report, Investing in Health. His publications are in the areas of economic theory, public health

and education.

Jamison studied at Stanford (M.S., engineering science) and at Harvard (Ph.D., economics, under K.J. Arrow). In 1994 he was elected to membership in the U.S. National Academy of Medicine. Jamison was recently co-first author, with Lawrence Summers, of 'Global Health 2035', the report of The Lancet Commission on Investing in Health. He is a member of ongoing Lancet commissions on tuberculosis and on palliative care. Jamison also serves on the World Bank Working Group on cost and finance of country-level pandemic preparedness.

## Felicia Knaul, PhD



Felicia Marie Knaul is the Director of the University of Miami Institute for Advanced Study of the Americas and a Professor at UM's Miller School of Medicine. She maintains a strong program of research and advocacy in Latin America, especially in Mexico, where she is the Senior Economist at the Mexican Health Foundation and Founding President of Tómatelo a Pecho, A.C. Dr. Knaul is also the President (2016-18) of the Latin American Union against Women's Cancers (ULACCAM).

As a result of her breast cancer experience, in 2008 Dr. Knaul founded Tómatelo a Pecho, a Mexico-based non-profit agency that

promotes research, advocacy, awareness, and early detection in Latin America. She has lectured globally on the challenge of breast cancer in low and middle-income countries, both as patient-advocate and health systems researcher. She recounts her personal experience in *Tómatelo a Pecho* (Grupo Santillana, 2009) and *Beauty without the Breast* (Harvard University Press/ Harvard Global Equity Initiative, 2013). Her story and her work have been featured in *Reforma*, *The Miami Herald*, *The Lancet*, *Science*, *WHO Bulletin*, *Newsweek en Español*, and *Cancer Today*.

Dr. Knaul has designed, created and coordinated several research networks. As Director of the Harvard Global Equity Initiative, she founded and directed the Global Task Force on Expanded Access to Cancer Care and Control, serving as lead author and co-editor of the task force's publication *Closing the Cancer Divide: An Equity Imperative* (Harvard University Press/ Harvard Global Equity Initiative, 2012), and was a member of the Global Task Force on Radiotherapy for Cancer Control (GTFRCC), taking a leadership role in the global reports that were produced. From 2012-2015, she was a member of the Lancet Commission on Women and Health and a leading co-author of its June 2015 report. Since 2014 she is the Chair of the Lancet Commission on Global Access to Palliative Care and Pain Control. Her areas of research are focused on global health and include cancer and especially breast cancer in low- and middle-income countries, women and health, health system strengthening and reform, health financing, and access to pain control and palliative care.

Dr. Knaul has produced more than 190 academic and policy publications, authored and lead-edited academic books, and serves on the advisory board or editorial board of several medical and health care publishers, including *The Lancet Global Health* and the *Journal of Global Oncology*, among others. She has also served on numerous boards, including the Union for International Cancer Control (2010-2014). Dr. Knaul received M.A. and Ph.D. degrees in economics from Harvard University and a B.A. in international development from the University of Toronto.

She and her husband, Dr. Julio Frenk, have two children, Hannah Sofia (20 and studying chemistry) and Mariana Havivah (12). Her mother Marie and brother Jonathan live in Canada.

## Rengaswamy Sankaranarayanan



Rengaswamy Sankaranarayanan was trained as radiation and clinical oncologist in the University of Kerala, India and had post-doctoral training at the Pittsburgh Cancer Institute, USA and the MRC Biostatistics Unit, Cambridge, UK. After working in primary care, clinical oncology and cancer control in India for about 11 years, Dr. Sankaranarayanan joined the International Agency for Research on Cancer (IARC) of the World Health Organization (WHO) in 1993, where he was the Head of the Early Detection and Prevention Section until 2014 and is currently the Special Advisor on Cancer Control and Head of the Screening Group. He is committed to research, training, program development and technical assistance in early detection and cancer control,

particularly in low- and middle income countries (LMICs). He has conceived, conducted and coordinated multinational studies in Asia, Africa and Latin America addressing feasible, affordable and effective methods of early detection and control of cervix, breast, colorectal and oral cancers and has also addressed survival outcomes from major cancers in LMICs. He has provided technical support to national cancer control programs and national screening programs in several LMICs. Dr Sankaranarayanan has taught in over 70 international courses on cancer early detection and control. He is an author in more than 260 papers in international peer-reviewed journals.

## Miriam Schneidman



Miriam Schneidman is a Lead Health Specialist in the Africa Region of the World Bank. She has more than 35 years of experience working on health and human development issues in the Africa and Latin America and Caribbean Regions of the World Bank.

Miriam Schneidman has led the design and development of investment operations in Africa (e.g. Burundi, Burkina Faso, Cameroon, Democratic Republic of Congo, Kenya, Rwanda, Nigeria, Tanzania, and Uganda) and Latin America and the Caribbean (e.g. Bolivia, Colombia, Haiti). She was extensively involved in the World Bank's Multi-Country HIV/AIDS Program for Africa (MAP), leading the roll-out of AIDS treatment programs, brokering partnerships, and managing several operations, including the Burkina and Rwanda MAPs. Over the past few years she has led a unique regional project in East Africa to strengthen diagnostic and surveillance systems. Most recently, she organized a South-South Knowledge Exchange to support countries in East and Southern Africa to share lessons and experiences in cancer care and control. In the past she worked extensively on family planning, reproductive health, and demographic issues.

Miriam Schneidman has written on the subject of vulnerable youth (*Targeting At-Risk Youth*, 1996), demographic issues (*Mortality and Fertility Trends in Zaire*, 1990), co-authored books and articles on women's health (*Women's Health in Latin America and the Caribbean*, 2001), performance based financing (*Performance Incentives for Global Health*, 2009), and laboratory systems (*Laboratory Professionals in Africa: The Backbone of Quality Diagnostics*, 2014) and cancer care and control (*Cancer Care and Control South-South Knowledge Exchange*, 2015).

Miriam Schneidman currently represents the World Bank on the Stop TB Partnership Coordinating Board. In the past she served as a member of the Center for Global Development Performance-Based Incentives Working Group and the Harvard Global Task Force on Expanded Access to Cancer Care and Control. Miriam Schneidman holds degrees in Economics from the University of Maryland and in Public Health from The Johns Hopkins University. She is fluent in French, Spanish and Romanian.

## Edward L. Trimble



In 2011 Dr. Harold Varmus, then Director of the US National Cancer Institute (NCI) appointed Dr. Trimble the founding Director of NCI's new Center for Global Health (CGH). Under Dr. Trimble's leadership CGH has become the coordinating point for NCI's work to strengthen global cancer research, to train future generations of global cancer researchers, and to help translate research into policy for cancer control. NCI CGH has been recognized worldwide for its work in the development of affordable cancer technology, national cancer control planning, and training.

From 1991 to 2011 Dr. Trimble worked in NCI's Division of Cancer Treatment and Diagnosis, with responsibility for national and international NCI-sponsored treatment trials in gynecologic cancer, as well as cancer trials for the elderly, adolescents and young adults, international collaboration in cancer clinical trials, and strengthening assessment of patient-reported outcomes and health-related quality of life in cancer trials. He spearheaded the NCI's Clinical Announcements regarding chemoradiation for cervical cancer (1999) and intraperitoneal chemotherapy for ovarian cancer (2006), both of which changed the standard of care for women with gynecologic cancer. For his work at the US NCI Dr. Trimble has received two Public Health Service Commendation Medals, six NIH Merit Awards, and the NCI Director's Gold Star Award.

Dr. Trimble graduated from Harvard University (BA), the Johns Hopkins University School of Medicine (MD), and the Johns Hopkins University Bloomberg School of Public Health (MPH). He trained in obstetrics/gynecology at Vanderbilt University Medical Center and in gynecologic oncology at Memorial Sloan-Kettering Cancer Center. He is board-certified in obstetrics and gynecology, as well as in gynecologic oncology, by the American Board of Obstetrics and Gynecology.

## KEY CONFERENCE TOPICS

1. Making global cancer control a development priority
2. Feasible, affordable and cost-effective cancer innovations from around the globe
3. Enhanced prevention (tobacco, vaccines)
4. Accelerating access to treatment
5. Presentation of the Disease Control Priorities 3 - Cancer Volume
6. Innovations in cancer promotion, care, palliation and funding
7. Addressing cancer needs of vulnerable populations
8. Global access to Radiotherapy
9. Engaging communities & governments: Taking Action for Cancer
10. Leveraging new technologies for improving access to cancer care and designing new interventions
11. Sustainable financing for cancer control
12. Follow-up meeting of the Lancet Commission on Global Tobacco Control
13. Innovations in Health Professional Training to meet growing cancer care needs
14. Developing young leaders and leverage millennial values for global cancer control
15. Women's and child health initiatives and global cancer control



## POTENTIAL SPEAKERS

Name	Title
Sir George Alleyne	Director Emeritus, Pan American Health Organization
Sanchia Aranda	CEO, Cancer Council Australia
Rifat Atun	Professor of Global Health Systems, Harvard University & Director of Global Health Systems Cluster at Harvard T.H. Chan School of Public Health
Otis Brawley	Chief Medical and Scientific Officer & Executive Vice President, American Cancer Society
David Collingridge	Editor-in-Chief, The Lancet Oncology & Publishing Director, The Lancet's Specialty Journals
Anil D'Cruz	Director, Tata Memorial Hospital & Professor and Chief, Department of Head and Neck Surgery
Eduardo Franco	Chair, Gerald Bronfman Department of Oncology, McGill University
Julio Frenk	President, University of Miami
Hellen Gelband	Associate Director for Policy, The Center for Disease Dynamics, Economics & Policy and Series Editor for DCP3
Meredith Giuliani	Radiation Oncologist, Princess Margaret Cancer Centre & Assistant Professor, Department of Radiation Oncology, University of Toronto
Mary Gospodarowicz	Professor of Radiation Oncology, University of Toronto; Medical Director, Princess Margaret Cancer Centre, & Regional Vice President, Cancer Care Ontario
Sumit Gupta	Staff Oncologist and Clinician Investigator, Haematology/Oncology, Hospital for Sick Children
Yolande Livens	President, ESTRO
David Jaffray	Senior Scientist, Princess Margaret Cancer Centre; Director, Research Institute, Techna Institute for the Advancement of Technology for Health; & Core Lead, Techna Institute for the Advancement of Technology for Health
Dean Jamison	Professor Emeritus, Global Health & Principal Investigator, Disease Control Priorities Network, University of Washington & Professor Emeritus, Global Health, University of California, San Francisco

Name	Title
Prabhat Jha	Professor in Global Health and Epidemiology & Canada Research Chair in Disease Control, Dalla Lana School of Public Health, U of T; & Founding Director, Centre for Global Health Research
Rama Khokha	Senior Scientist & Director, Research Institute, Princess Margaret Cancer Centre
Felicia Knaul	Professor, Department of Public Health Sciences at the Miller School of Medicine & Director, Institute for Advanced Study of the Americas, University of Miami
Amit Oza	Senior Staff Physician, Princess Margaret Cancer Centre & Professor of Medicine at the University of Toronto
Gary Rodin	Senior Scientist, Princess Margaret Cancer Centre & Toronto General Research Institute
Rengaswamy Sankaranarayanan	Special Advisor on Cancer Control and Chief of the Cancer Screening Group at the International Agency for Research on Cancer
Miriam Schneideman	Lead Health Specialist, World Bank Africa Region
Don Tapscott	CEO, The Tapscott Group
Edward Trimble	Director, National Cancer Institute Center for Global Health
May Abdel Wahab	Director, Division of Human Health, International Atomic Energy Agency

# 2 | PROPOSED PROGRAM AT A GLANCE

THURSDAY MARCH 1, 2018

7:15-8:15	Breakfast and Registration		
8:15-8:45	Welcome and Introductions		
8:45-10:30	Keynote		
	Plenary/Panel Session		
10:30-10:45	Refreshment Break		
10:45-12:30 Concurrent Sessions	Maternal/Child/Women Cancer <i>Diagnosis/Treatment/Genomics Rare Cancers</i>	Palliative/Supportive Care <i>Pain Control</i>	Prevention/Screening/Tobacco Control
12:30-13:30	Lunch		
13:30-15:00 Concurrent Sessions	Concurrent Sessions Innovation/Education	Health Policy/Economics/ Cancer Control Networks <i>Forgotten Population/ Access/HR</i>	Young Leaders



15:00-15:30	Refreshment Break		
	Café Session	Café Session	Café Session
15:30-16:30	Panel Session		
16:30-17:30	Poster/Rapid Fire	Poster/Rapid Fire	Poster/Rapid Fire
17:30-19:00	Welcome Reception		

## FRIDAY MARCH 2, 2018

7:15-8:45	Breakfast and Registration		
8:45-10:30	Keynote		
	Plenary/Panel		
10:30-10:45	Refreshment Break		
10:45-12:30 Concurrent Sessions	Maternal/Child/Women Cancer <i>Diagnosis/Treatment/Genomics Rare Cancers</i>	Palliative/Supportive Care <i>Pain Control</i>	Prevention/Screening/Tobacco Control
12:30-13:30	Lunch		
13:30-15:00 Concurrent Sessions	Concurrent Sessions	Health Policy/Economics/ Cancer Control	Young Leaders

	Innovation/Education	Networks <i>Forgotten Population/</i> <i>Access/HR</i>	
15:00-15:30	Refreshment Break		
15:00-15:30	Café Session	Café Session	Café Session
15:30-16:30	Panel Session		
16:30-17:30	Poster/Rapid Fire	Poster/Rapid Fire	Poster/Rapid Fire

## SATURDAY MARCH 3, 2018

8:00-9:00	Breakfast and Registration		
9:00-10:00	Poster/Rapid Fire	Poster/Rapid Fire	Poster/Rapid Fire
10:00-11:00	Keynote		
11:00-12:30 Concurrent Sessions	Empowering Networks in Global Cancer Care	Artificial Intelligence and Digital Solutions	Young Leaders
12:30-12:45	Closing Remarks		

# 3 | PARTNERSHIP OPPORTUNITIES

Partnership with the Toronto Global Cancer Control Conference is an excellent way for your organization to:

➤ **Promote**

Business, scientific, and advocacy solutions to an audience of major industry leaders while fostering opportunities with key physicians and health care professionals from Canada and around the world

➤ **Show Your Support**

For the Dalla Lana School of Public Health, Princess Margaret Cancer Centre and all colleagues in Canada and abroad leading the fight to prevent and treat cancer

➤ **Be Recognized**

Within the medical, global health and research communities as a valued and trusted partner in the fight against cancer

Your partnership provides opportunities to:

- Meet and work with Canadian and international policy makers and related stakeholders in VIP setting
- Direct access to conference delegates via the Industry Partners Exhibition – (i.e. marketplace/booth environment)
- Opportunity to sponsor hospitality for general admission delegates
- Brand marketing overlays

**30**

Number of countries participating in the Toronto Global Cancer Control Conference

**350**

Number of participating cancer, global health experts and political leaders

## PARTNERSHIP LEVELS & BENEFITS

### Gold - \$75,000 (3)

- All benefits of Silver level partnership
- Opportunity to purchase one (1) partnered breakfast (Fri. or Sat.) or lunch (Sat.) at additional cost of \$2,500
- Four (4) VIP tickets to private reception with conference's international leadership committee and distinguished guests
- Six (6) full conference registrations for company representatives
- First level partnership listing in conference program

### Silver – \$25,000 (4)

- All benefits of Bronze level partnership
- Two (2) full conference registrations for company representatives
- Two (2) exhibitor passes for company representatives
- Acknowledgment on signage at the conference facility
- Second level partnership listing in conference program
- Acknowledgment on conference website - [GlobalCancerControlConference.com](http://GlobalCancerControlConference.com) - with active web link to your website
- Opening ceremonies introduction and acknowledgement from the podium

### Bronze – \$15,000 (10)

- All benefits of Exhibitor level partnership
- One (1) full conference registrations for company representatives
- One (1) exhibitor passes for company representatives
- Acknowledgment on signage at the conference facility
- Second level partnership listing in conference program
- Acknowledgment on conference website - [GlobalCancerControlConference.com](http://GlobalCancerControlConference.com)

### Exhibitor (non-profit only) – \$5,000

- One exhibit spot consisting of one 6' table with 2 chairs
- One (1) exhibitor pass for company representatives
- Exhibitor listing on the website and program
- On-site signage – recognition on the industry partners' board



For more information, please contact:

**Ryan Lindsay**  
Senior Development Officer  
Dalla Lana School of Public Health  
Health Sciences Building  
155 College Street, 6<sup>th</sup> Floor  
Toronto, ON M5T 3M7

ryan.lindsay@utoronto.ca  
1.416.978.1235

*Note: Partnerships do not include coverage of travel, registration, hotel and all other expenses related to the partner representatives or their guests, and presenter cannot receive honorariums for their time due to the conference being accredited. Conference organizers reserve the right to make changes to the floorplan at all times.*



UNIVERSITY OF TORONTO  
DALLA LANA SCHOOL OF PUBLIC HEALTH

